Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irsenontrine
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Irsenontrine is a selective, oral small molecule inhibitor of phosphodiesterase 9A (PDE9A), an enzyme that degrades cyclic guanosine monophosphate (cGMP). By inhibiting PDE9A, irsenontrine increases cGMP levels in the brain, which is believed to enhance synaptic function and memory. It has been developed primarily for the treatment of dementia with Lewy bodies and has also been studied in Parkinson’s disease dementia. Clinical trials have shown robust pharmacodynamic effects on CSF cGMP but did not meet primary cognitive endpoints in phase II/III studies. The drug was developed by Eisai and remains investigational[1][4][6][7].
- Other names
- Irsenontrine maleate
02
Targets
PDE9A (Phosphodiesterase 9A)
Beyond the preview
Go deeper on Irsenontrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Irsenontrine.